More clinical lessons from the FIELD study

Research output: Contribution to journalArticle

10 Scopus citations


Introduction: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes. Results and discussion: Reduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11%), but only significant for total CVD events (p∈=∈0.035). The benefit of fenofibrate treatment was greater in patients with mixed dyslipidaemia, especially in those with triglycerides >2.3 mmol/L and low plasma levels of high-density lipoprotein cholesterol (relative risk reduction 27%, p∈=∈0.005). There were also microvascular benefits associated with fenofibrate treatment, specifically reduction in the rate of laser therapy for retinopathy (by 30%, p∈

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalCardiovascular Drugs and Therapy
Issue number3
Publication statusPublished - Jun 2009
Externally publishedYes



  • Cardiovascular disease
  • Fenofibrate
  • Retinopathy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this